Clinical trial · Interventional
Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Nilotinib) Therapy
NCT01490983CI-TRIAL-00034331terminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Terminated due to lack of funding
Summary
Brief summary (as posted)
This study is being conducted in a population of patients with chronic phase Chronic Myeloid Leukemia (CML) to learn more about how patients follow prescribed regimens for taking oral cancer drugs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| eMedonline access | Behavioral | — | UNRESOLVED |
| no access to eMedonline | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- eMedonline access
- description
- patients will have access to eMedonline access for 3 months
- interventionNames
- Behavioral: eMedonline access
- type
- OTHER
- label
- no access to eMedonline
- description
- patients will be followed for 3 months with no access to eMedonline
- interventionNames
- Behavioral: no access to eMedonline
Primary outcomes (1)
- measure
- eMedonline will be used to measure non-compliance in taking oral drug regimens.
- timeFrame
- at 6 months, non-compliance will be measured in each arm of study
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years of age or older. * Pathologically documented diagnosis of Chronic Phase CML (Ph+) in whom treating physician has determined that treatment with imatinib or nilotinib is appropriate * Patients currently receiving Gleevec (imatinib) 300-600 mg daily or Tasigna (nilotinib) 300-400 mg twice daily * ECOG Performance status 0, 1, or 2 * Adequate end organ function, defined as: * Total bilirubin \< 1.5 xULN * SGOT and SGPT \<2.5 x ULN * Creatinine \< 1.5 x ULN * ANC \> 1.5 * Platelets \> 100,000 * Female patients of child bearing potential must have a negative urine or serum pregnancy test at screening. * Patient is able to read and speak English * Patient is willing and able to use a cell phone * Written, voluntary informed consent Exclusion Criteria: * Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.